NewsBenzinga日曜日に報告、Cabalettaは、rese-celが皮膚筋炎、ループス腎炎、全身性強皮症において少なくとも1年間にわたり免疫調節薬を使わない反応をもたらしたと発表;筋炎のBLAは2028年 第1四半期に申請予定 日曜日に報告、Cabalettaは、rese-celが皮膚筋炎、ループス腎炎、全身性強皮症において少なくとも1年間にわたり免疫調節薬を使わない反応をもたらしたと発表;筋炎のBLAは2028年 第1四半期に申請予定 Benzinga 2026.11.09 08:13 (GMT+0) Open on Benzinga Other news 'China Taps US AI Models To Train Homegrown Rivals As Chip Curbs Bite' - Reuters Exclusive 'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century' A-Share Close: ChiNext Index Down Over 1% After Intraday Reversal, More Than 4,100 Stocks Fall Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen Aytu BioPharma Stock Climbs 44% After-Hours: Here's Why Reported Earlier, MediaCo Holding Q3 EPS $(0.11) Up From $(0.22) YoY, Sales $28.600M Down From $35.398M YoY
'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century'
Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen
Reported Earlier, MediaCo Holding Q3 EPS $(0.11) Up From $(0.22) YoY, Sales $28.600M Down From $35.398M YoY